Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG -- Ignore unavailable to you. Want to Upgrade?

To: swisstrader who wrote (395)	1/19/2000 1:49:00 PM
From: Cheryl Galt	Read Replies (1) \| Respond to of 804

Celgene Files Registration Statement for Public Offering WARREN, N.J., Jan. 19 /PRNewswire/ -- Celgene Corporation today announced the filing of a registration statement with the Securities and Exchange Commission for an offering of 2,416,000 shares of its common stock. Of the shares offered, 2,000,000 shares are being offered by Celgene for its own account. The remaining 416,000 shares are being sold on behalf of John Hancock Mutual Life Insurance Company and its affiliates. Celgene will also grant to the underwriters an option to purchase an additional 362,400 shares of common stock to cover over-allotments. Celgene intends to use its net proceeds from this offering to further the commercialization and clinical development of Thalomid©, to accelerate the advancement of its IMiD(TM) and SelCID(TM) product development programs, to further develop its chiral chemistry program, including ATTENADE(TM), and for general corporate purposes. Celgene will not receive any proceeds from the sale of shares by John Hancock Mutual Life Insurance Company and its affiliates. J. P. Morgan & Co. and Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated are the joint lead managers of the offering. U.S. Bancorp Piper Jaffray is acting as co-manager. ....